Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Outcome of hospitalized covid 19 patients with underlying respiratory illness in second and third wave.

J T.Kutty, B Madhav, D Revande, G Bathe
European Respiratory Journal 2022 60: 3138; DOI: 10.1183/13993003.congress-2022.3138
J T.Kutty
Apollo Hospitals Navi Mumbai, Navi Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B Madhav
Apollo Hospitals Navi Mumbai, Navi Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D Revande
Apollo Hospitals Navi Mumbai, Navi Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G Bathe
Apollo Hospitals Navi Mumbai, Navi Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

Background:-Since patients with respiratory disorders are prone to serious covid-19 illness we wanted to see the outcome of such patients.

Objective:-To study outcome of covid-19 patients with underlying respiratory illness and their ICU requirement, oxygen requirement and mortality.

Method:-Retrospective analysis of 100 covid positive patients with respiratory illnesses in 2nd wave and 18 covid positive patients in 3rd wave was done.

Results:-Among patients admitted with covid 19 with respiratory illness 38% required ICU. In second wave maximum belonged to bronchial asthma group and in third wave maxmimum patients belonged to COPD group. Maximum oxygen requirement noted in ILD group in second wave and COPD group in third wave. Total cases admitted during 2nd wave period was 4216 death rate was 7.2% in whole group and 12% in respiratory illness group. Total admissions in the 3rd wave were 550,death rate was 4.36 % in the whole group and 27% in respiratory illness group. Maximum mortality seen in ILD group in second wave and COPD group in third wave. Higher oxygen utilization, ICU requirement and death were seen in ILD subgroup.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Conclusion:- Around 40% of patients with pre-existing respiratory illness required ICU admission. They had high incidence of oxygen requirement, non-invasive ventilation, and mechanical ventilation. The death rate was higher in patients with underlying respiratory illness.

  • Covid-19
  • Treatments
  • Behavioral science

Footnotes

Cite this article as Eur Respir J 2022; 60: Suppl. 66, 3138.

This article was presented at the 2022 ERS International Congress, in session “-”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2022
Previous
Back to top
Vol 60 Issue suppl 66 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Outcome of hospitalized covid 19 patients with underlying respiratory illness in second and third wave.
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Outcome of hospitalized covid 19 patients with underlying respiratory illness in second and third wave.
J T.Kutty, B Madhav, D Revande, G Bathe
European Respiratory Journal Sep 2022, 60 (suppl 66) 3138; DOI: 10.1183/13993003.congress-2022.3138

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Outcome of hospitalized covid 19 patients with underlying respiratory illness in second and third wave.
J T.Kutty, B Madhav, D Revande, G Bathe
European Respiratory Journal Sep 2022, 60 (suppl 66) 3138; DOI: 10.1183/13993003.congress-2022.3138
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • SPRINTER: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Determine the Efficacy and Safety of Inhaled Interferon Beta-1a (SNG001) for the Treatment of Patients Hospitalised Due to COVID-19 (NCT04732949)
  • A randomised controlled trial of early intervention with oral favipiravir in patients hospitalised with COVID-19 (PIONEER Trial)
  • Dipeptidyl Peptidase-1 Inhibition in Patients Hospitalized with COVID-19: a Multicentre Randomized Double-Blind Placebo Controlled Trial
Show more 10.01 - Respiratory infections and bronchiectasis

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society